Alliance Global Partners lowered the firm’s price target on DarioHealth to $2.50 from $4.10 and keeps a Buy rating on the shares as the firm is adjusting its model based on Q3 results and the company’s implied 2024 guidance. Despite the reduced price target, the firm believes DarioHealth shares “offer a significantly favorable risk-return trade-off,” says the analyst, who notes that although the firm lowered its revenue estimate “meaningfully,” it now forecasts better bottomline results for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DRIO:
- DarioHealth reports Q3 EPS (49c), consensus (46c)
- DarioHealth Reports Third Quarter 2023 Financial and Operating Results
- DarioHealth launches new smart blood sugar meter for Apple iPhone 15
- DarioHealth to host investor day
- DarioHealth’s Dario shows reduction of diabetes patient hospital readmissions
